The 1 analysts offering 12-month price forecasts for PDL BioPharma Inc have a median target of 2.78, with a high estimate of 2.78 and a low estimate of 2.78. The median estimate represents a +27.66% increase from the last price of 2.17.
The current consensus among 1 polled investment analysts is to Hold stock in PDL BioPharma Inc. This rating has held steady since February, when it was downgraded from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $0.06
Reporting Date Nov 11
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.